Business Standard

Saturday, December 21, 2024 | 05:11 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

India's Serum Institute to make Novavax's Covid vaccine for US market

The company has indicated in the first quarter earnings call that it has reached a major milestone in its pathway to an emergency use authorisation from the US Food and Drugs Administration

Serum Institute
Premium

Meanwhile, SII is getting ready to work with its US partner Novavax on an Omicron variant-specific vaccine for Covid-19 that will be different from the original shot developed by the US major using the Wuhan strain of the Sars-CoV-2 virus | Photo: Abhishek Waghmare

Sohini Das Mumbai
US major Novavax has said its Covid-19 vaccine (NVX-CoV2373) for adults — to be used in the US following an approval from the USFDA — would be manufactured by its Indian partner Serum Institute of India (SII).

According to Reuters, Novavax’s Chief Medical Officer Filip Dubovsky said on Tuesday that all vaccines being distributed commercially across the world “are being made in a single facility by our partners (the Serum Institute in India — SII) that includes the vaccines which are being deployed around the world as well as the ones that will be initially deployed in the US”.

The company has

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in